Compare Citius Pharmaceuticals Inc (CTXR) vs GE Aerospace (GE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs GE Aerospace — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while GE Aerospace trades at $306.99 (market cap $317.10B). The key difference: GE Aerospace is far larger — about 23281.9× Citius Pharmaceuticals Inc's market cap, and GE Aerospace pays a 0.62% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and GE Aerospace for 111 Days on average.
| CTXR | GE | |
|---|---|---|
Market Cap | $13.62M | $317.10B |
Volume | 132,438 | 6,320,106 |
Sector | Health | Industrials |
52-Week High | $1.82 | $381.22 |
52-Week Low | $0.48 | $273.25 |
Typical Hold Time | 16 Days | 111 Days |
Enterprise Value | $3.79M | $326.91B |
Dividend Yield | — | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
GE Aerospace trades at $305.62, down 1.22% amid broader market weakness, with technical indicators showing bearish momentum below key moving averages. Fundamentally, the company demonstrates strong profitability with 17.72% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news highlights the strategic $12 billion CPP acquisition to address supply chain constraints while maintaining robust shareholder returns through dividends and buybacks.
The outlook remains constructive given strong defense demand and operational execution, but high valuation and acquisition integration risks warrant caution. Analyst consensus is strongly bullish with a $409.60 price target representing 34% upside, though near-term technical pressure may persist until the Q3 earnings report provides clearer direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
